ILMN ILLUMINA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1110803 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY27.5%
TTM EPS YoY30.3%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin67.9%
Operating margin21.2%
Net margin19.7%
FCF margin23.3%
EBITDA margin27.1%
Returns
ROE32.4%
ROA13.8%
ROIC (approx.)51.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity0.00x
Current ratio2.63x
Interest coverage9.80x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 |
|---|---|---|
| Income statement | ||
| Revenue | $4.34B | $4.37B |
| Cost of revenue | $1.47B | $1.51B |
| Gross profit | $2.87B | $2.86B |
| R&D expense | $967.00M | $1.17B |
| SG&A expense | $1.09B | $1.09B |
| Operating income | $807.00M | -$833.00M |
| Interest expense | $101.00M | $100.00M |
| Pretax income | $1.09B | -$1.18B |
| Income tax | $236.00M | $44.00M |
| Net income | $850.00M | -$1.22B |
| EBITDA | $1.08B | -$479.00M |
| EPS (basic) | 5.47 | -7.69 |
| EPS (diluted) | 5.45 | -7.69 |
| Weighted avg. shares (diluted) | 156.00M | 159.00M |
| Balance sheet | ||
| Cash & equivalents | $1.42B | $1.13B |
| Short-term investments | $215.00M | $93.00M |
| Receivables | $854.00M | $735.00M |
| Inventory | $564.00M | $547.00M |
| Current assets | $3.29B | $2.75B |
| PP&E, net | $759.00M | $815.00M |
| Goodwill | $1.11B | $1.11B |
| Intangibles | $210.00M | $295.00M |
| Total assets | $6.64B | $6.30B |
| Current liabilities | $1.58B | $1.55B |
| Total liabilities | $3.92B | $3.93B |
| Shareholders' equity | $2.72B | $2.37B |
| Shares outstanding | 153.00M | 159.00M |
| Cash flow statement | ||
| Operating cash flow | $1.08B | $837.00M |
| Capital expenditure | $148.00M | $128.00M |
| Free cash flow | $931.00M | $709.00M |
| Investing cash flow | -$55.00M | -$178.00M |
| Financing cash flow | -$744.00M | -$570.00M |
| Depreciation & amortization | $270.00M | $354.00M |
| Stock-based compensation | $275.00M | $370.00M |
| Share buybacks | $742.00M | $116.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.